Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 12 systematic review(s)/meta-analysis(es). ^[1-12]
• Pain Freedom at 2 Hours Post-Dose: Ubrogepant demonstrated superior efficacy compared to placebo, with comparable effectiveness to rimegepant and lasmiditan but less effectiveness than triptans such as eletriptan, rizatriptan, sumatriptan, and zolmitriptan.
• Sustained Pain Freedom from 2 to 24 Hours: Ubrogepant was effective for sustained pain freedom but less so than ibuprofen and eletriptan, with rimegepant showing superior outcomes in this category.
• Freedom from Most Bothersome Symptom at 2 Hours: Ubrogepant was effective but less effective compared to higher doses of lasmiditan; specifically, lasmiditan at 100 mg and 200 mg showed better outcomes.
• Pain Relief at 2 Hours: Ubrogepant provided comparable pain relief to rimegepant and lasmiditan but was less effective than triptans, which demonstrated better outcomes for pain relief within the same timeframe.
• General Safety Profile: Ubrogepant was generally well-tolerated, with the incidence of adverse events comparable to placebo; however, a higher incidence of adverse events was observed at the 100 mg dose compared to the 50 mg dose. It exhibited a better tolerability profile than lasmiditan and rimegepant, especially concerning neurological adverse events such as dizziness and somnolence.
• Adverse Events: Common adverse events associated with ubrogepant included nausea, dry mouth, and somnolence, with increased adverse events at the 100 mg dose. In comparison, lasmiditan presented the highest risk of adverse events, including dizziness and fatigue, while rimegepant had fewer adverse events than lasmiditan but more than ubrogepant.
• Safety in Specific Populations: Safety outcomes for ubrogepant were consistent between participants using preventive medications and those not using them, indicating no significant interaction or added risk. No serious treatment-related adverse events were reported in long-term safety trials of ubrogepant.
• Population Types and Gender Considerations: All studies focused on adults aged 18 years and older diagnosed with migraine, with over 80% of participants being female. Efficacy and safety outcomes for ubrogepant were similar in users and non-users of preventive medications, indicating its safe use alongside such treatments. The predominance of female participants suggests a need for further studies to confirm the effectiveness and safety of ubrogepant across different age groups and in male populations.